Costs and Health Outcomes Associated with Tofacitinib Treatment for Active Psoriatic Arthritis in the United States

BACKGROUND: Psoriatic arthritis (PsA) is a chronic progressive inflammatory condition associated with significant direct and indirect costs. Tofacitinib is an oral Janus kinase inhibitor for the treatment of PsA. Economic evaluations, alongside clinical data, help inform papers and formulary decisio...

Descripción completa

Detalles Bibliográficos
Autores principales: Bungey, George, Chang-Douglass, Stacey, Hsu, Ming-Ann, Cappelleri, Joseph C., Young, Pamela, Woolcott, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391130/
https://www.ncbi.nlm.nih.gov/pubmed/32308099
http://dx.doi.org/10.18553/jmcp.2020.19319

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391130/
https://www.ncbi.nlm.nih.gov/pubmed/32308099
http://dx.doi.org/10.18553/jmcp.2020.19319

Ejemplares similares